PulmCCM

Share this post

NSCLC: Use of biomarkers in prognosis, treatment

www.pulmccm.org

NSCLC: Use of biomarkers in prognosis, treatment

Sep 28, 2011
Share this post

NSCLC: Use of biomarkers in prognosis, treatment

www.pulmccm.org

37 Canadian oncologists got together in a consensus panel to talk about biomarkers and histologic subtypes of non-small cell lung cancer.

The take-home:

  • All NSCLC should be tested for the EGFR mutation, as tyrosine kinase inhibitors can prolong survival for eligible patients.

  • There is insufficient evidence to recommend routine testing for other mutations (KRAS, p53, VEGF, EML4/ALK, etc).

  • Squamous cell may have a worse prognosis than adenocarcinoma.

  • Whenever possible, get biopsy tissue from a solid tumor, rather than just cytology, to enhance yield of subtyping.

Ellis P et al. A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. J Thorac Oncol 2011;6:1379-1391.

Share this post

NSCLC: Use of biomarkers in prognosis, treatment

www.pulmccm.org
Comments
TopNew

No posts

Ready for more?

© 2023 PulmCCM
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing